Anthrax Protective Antigen-directed Antibody Interactions [MoA] - N0000192702

Name: Table of NDC products with anthrax protective antigen-directed antibody interactions
Creator: U.S. Food & Drug Administration
License: https://creativecommons.org/licenses/by-nc-sa/4.0/

Pharmacologic Class Information

Pharmacologic Code	N0000192702
Pharmacologic Name	Anthrax Protective Antigen-directed Antibody Interactions
Pharmacologic Uses	monoclonal antibody directed against the protective antigen of Bacillus anthracis
Pharmacologic Concept	Mechanisms of Action - [MoA]
Pharmacologic Concept Description	This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

NDC Products with Anthrax Protective Antigen-directed Antibody Interactions

The table contains 2 products whose active ingredient are classified under the same pharmacologic class Anthrax Protective Antigen-directed Antibody Interactions [MoA].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	69604-204	Anthim	Non-Proprietary Name: Obiltoxaximab	Solution	Intravenous	Elusys Therapeutics, Inc.	ACTIVE
	71655-103	Raxibacumab	Non-Proprietary Name: Raxibacumab	Injection	Intravenous	Emergent Manufacturing Operations Baltimore Llc	ACTIVE